Drug Research
FDA Approves Zepatier (elbasvir and grazoprevir) for Chronic Hepatitis C Genotypes 1 and 4
The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus...
News
Bayer reinforces its commitment to supporting partners along the food value chain with sustainable agricultural solutions
Bayer is committed to delivering sustainable agricultural solutions to overcome today’s challenges and contribute towards meeting the sustainable development goals of the United Nations....
News
Merck Completes Enrollment in Pivotal Phase 3 “EPOCH” Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer’s Disease
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today confirmed the completion of enrollment for the EPOCH trial, a Phase...
Press Releases
Changes to the Roche Corporate Executive Committee
Silvia Ayyoubi (62), Head of Group Human Resources for Roche and member of the Corporate Executive Committee has decided to retire from Roche following...
Press Releases
Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NSYE:PFE) today announced that the companies have entered into a collaboration agreement with Portola Pharmaceuticals Inc. (Nasdaq:...
Press Releases
Bristol-Myers Squibb Foundation Awards Eight Grants Totaling Nearly $11.5M to Make Lung and Skin Cancer Screening, Care More Accessible in High-Risk U.S. Communities
"The grant from the Bristol-Myers Squibb Foundation will allow us the opportunity to better reach and inform these at-risk patients in our area and...
Techno Trends
Novartis Access
The menace of noncommunicable diseases (NCDs) like cardiovascular diseases, diabetes and cancer in the developing world is increasing. These conditions disproportionally affect poverty-stricken areas....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read